uniQure NV is a pharmaceutical company based in the Netherlands, specializing in gene therapy. With an ESG score of 29.1, it is considered a medium-risk investment. uniQure NV develops innovative treatments for a variety of genetic and severe diseases, including hemophilia, Huntington's disease, and cardiovascular conditions. The company is actively expanding its pipeline of gene therapies through collaborations, particularly with Bristol Myers Squibb for cardiovascular diseases. Invest in uniQure NV for cutting-edge solutions in the pharmaceutical industry.